AIIMS Delhi Completes India's First Brain Stent Clinical Trial, Achieves Regulatory Approval for Stroke Treatment
核心洞察
AIIMS Delhi (搜索) successfully conducted India's first dedicated clinical trial of the Supernova brain (搜索) stent, demonstrating excellent safety and efficacy outcomes for severe stroke (搜索) treatment.
The GRASSROOT trial results led to regulatory approval by India's Central Drugs Standard Control Organisation (搜索), marking the nation's first stroke (搜索) device cleared based on domestic clinical evidence.
The Supernova stent (搜索), designed specifically for India's younger stroke (搜索) patient population, will be manufactured locally at affordable prices to serve the 1.7 million Indians who suffer strokes annually.
AIIMS Delhi (搜索) has achieved a significant milestone in stroke (搜索) care by successfully completing the country's first dedicated clinical trial of an advanced brain (搜索) stent designed for treating severe strokes. The GRASSROOT trial, which evaluated the Supernova stent (搜索) developed by Gravity Medical Technology (搜索), demonstrated excellent safety and efficacy outcomes and has resulted in regulatory approval for routine clinical use.
Landmark Clinical Trial Achievement
The GRASSROOT trial represents a turning point for stroke (搜索) treatment in India, according to Dr Shailesh B Gaikwad, professor and head of the Department of Neuroimaging and Interventional Neuroradiology at AIIMS Delhi (搜索) and national principal investigator of the study. AIIMS Delhi served as both the national coordinating centre and lead enrolling site for this groundbreaking trial.
"This trial is a turning point for stroke (搜索) treatment in India," Dr Gaikwad stated. The study was conducted across eight centres throughout the country, marking a significant advancement in India's clinical research capabilities.
Regulatory Approval and Clinical Impact
Earlier this year, data from the GRASSROOT trial were accepted by the Central Drugs Standard Control Organisation (搜索) (CDSCO), leading to approval of the Supernova stent (搜索)-retriever for routine use in India. This achievement represents the nation's first stroke (搜索) device cleared based on a domestic clinical trial.
"This is the nation's first stroke (搜索) device cleared based on a domestic clinical trial. The approval follows the GRASSROOT India trial, which confirmed the device's safety and efficacy in treating life-threatening strokes," AIIMS stated in an official announcement.
The trial results have been published in the Journal of Neurointerventional Surgery (JNIS), part of the prestigious British Medical Journal group, providing international recognition for the research conducted entirely within India.
Device Design and Patient Population
The Supernova stent (搜索) was specifically developed by Gravity Medical Technology (搜索) for India's diverse patient population, where strokes often affect patients at a younger age compared to Western populations. Dr Dileep Yavagal, professor of neurology and neurosurgery at the University of Miami and Global Principal Investigator of the GRASSROOT trial, noted that "the device has already treated more than 300 patients in Southeast Asia."
Dr Yavagal emphasized the device's potential impact, stating it "will now be manufactured and made available in India at affordable prices, offering new hope to the 1.7 million Indians who suffer strokes each year."
Make-in-India Initiative and Global Positioning
The successful completion of this trial marks a significant milestone for India's Make-in-India initiative and positions the country as a global player in advanced stroke (搜索) care. Dr Ashutosh Jadhav, Chief Scientific Officer at Gravity Medical Technology (搜索), highlighted that the effort produced "world-class clinical evidence entirely within the country" and built a "robust framework for future large-scale, high-quality trials."
Dr Shashvat M Desai, Chief Technology Officer at Gravity Medical Technology (搜索), described the approval as "more than just a regulatory milestone," noting that "this achievement demonstrates that India can design and deliver clinical trials of global significance, accelerating access to advanced therapies while upholding equity."
Clinical Excellence and Future Impact
Dr Deepti Vibha, professor of neurology at AIIMS Delhi (搜索), emphasized the crucial role of patient and family participation in the trial, stating their involvement will "bring faster, more affordable treatments to millions." The trial's success stands as a testament to the expertise of Indian clinical leaders, with Dr Desai noting the contribution of Dr Gaikwad and his team, who bring over three decades of experience in advancing stroke (搜索) treatment.
The GRASSROOT trial's completion and subsequent device approval demonstrate India's growing capability in conducting high-quality clinical research while addressing the specific medical needs of its population through locally developed and manufactured medical devices.